Articles related to IRRITABLE BOWEL SYNDROME (IBS)

Recent studies suggest that the artificial sweetener neotame may undermine the structural integrity of the gut and enhance undesirable bacterial behaviors, such as increased biofilm production.

This CME program hopes to enrich your understanding of IBD management, specifically focusing on biologic failure and surgical advancements.

The American Journal of Gastroenterology published the ACG clinical guideline on the management of IBS in January 2021. Lead author gastroenterologist Brian E. Lacy, MD, PhD, says that to diagnose IBS, clinicians should take a careful history, perform a careful physical exam, use Rome IV criteria, and perform limited diagnostic testing (complete blood count, C-reactive protein, and possibly celiac serologies and fecal calprotectin, depending on symptoms). Regardless of whether a patient has constipation-predominant symptoms, diarrhea-predominant symptoms, or a combination of constipation and diarrhea, the first step is to classify the patient into a mild, moderate, or severe IBS category.

The research shows that chronic pain, inflammatory bowel disease, cancer, and migraines all play a role in the development of mental diseases. Healthcare practitioners should take a careful history and keep in mind comorbidities when treating patients for any of these conditions.

The research, taken from the CLARITY study and published in GUT, found that 865 people given the Pfizer/BioNTech or the Oxford/AZ COVID-19 vaccine and treated with infliximab (Remicade) had significantly lower concentrations of antibodies when compared to 428 people on an alternative treatment, vedolizumab (Entyvio). Infliximab is prescribed to around two million people worldwide.